The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 15.45 — safe zoneOK
Where the revenue comes from
Fiscal 2025, as LENZ Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- License revenue$17.5M
- Product sales, net$1.6M
Leadership changes
From LENZ Therapeutics, Inc.'s own filings, the day they're filed.
- Frederic Guerard · directors · appointmenteff. 2024-03-21
- James McCollum · directors · appointmenteff. 2024-03-21
- Jeff George · directors · appointmenteff. 2024-03-21
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-12
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about LENZ Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when LENZ Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.